INTERNATIONAL PATENT: REZQ BIO, INC. FILES APPLICATION FOR "TOLEROGENIC DENDRITIC CELLS AS AN ADJUNCT TO STEM CELL-DERIVED B-CELL REPLACEMENT THERAPY FOR TYPE 1 DIABETES"

GENEVA, Dec. 31 -- REZQ BIO, INC. (2635 E. Carson StreetSuite 338Pittsburgh, Pennsylvania 15203) filed a patent application (PCT/US2025/034607) for "TOLEROGENIC DENDRITIC CELLS AS AN ADJUNCT TO STEM CELL-DERIVED B-CELL REPLACEMENT THERAPY FOR TYPE 1 DIABETES" on Jun 20, 2025. With publication no. WO/2025/265064, the details related to the patent application was published on Dec 26, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): GREENE, Douglas A. (c/o Rezq Bio, Inc.2635 E. Carson StreetSuite 338Pittsburgh, Pennsylvania 15203), FINEGOLD, David (c/o Rezq Bio, Inc.2635 E. Carson StreetSuite 33...